Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The commercial production in the SML was started in November 1989. Today SML, with a consolidated revenue of R 1,159.76 crore for the year 2021-22 against the previous years’ revenue of Rs 931.27 crore, has emerged as a global brand within manufacturing and supplying of affordable API and Formulation globally in different regulated markets. The Group with over 20 subsidiaries is now setting up a greenfield project located in Karnataka. BioSpectrum India spoke to Vishnukant Bhutada, Managing Director, Shilpa Medicare Limited on the new facility and challenges and growth of the company. Edited excerpts;
Bio-pharma Market to Witness Huge Growth by 2026 | Pfizer, Amgen, Bayer AG texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Bio-pharma Market is touching new levels - A comprehensive study segmented by Key Players: Bristol-Myers Squibb, Biogen, Sanofi, Amgen, AbbVie sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.